We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Apollo Life Sciences has announced that it is starting preclinical trials of a tablet TNF blocker for arthritis using its Oradel oral-delivery system in tandem with its ALS-00T2 TNF blocker, which was developed especially for delivery in tablet form.
TargeGen has begun a single-site Phase I clinical trial involving TG100801, a small-molecule, topically applied, multitargeted kinase inhibitor for the treatment of age-related macular degeneration (AMD) and other debilitating diseases of the eye.
AstraZeneca has announced its intention to expand the development plan for CytoFab, a treatment for severe sepsis, with the addition of a 480-patient Phase II study.
PTC Therapeutics has announced the findings from two Phase II clinical trials of PTC124 in patients with cystic fibrosis (CF) due to a nonsense mutation.
Cell Therapeutics announced that enrollment in its PIONEER lung cancer clinical trial has been temporarily suspended while the company awaits follow-up data of recently enrolled patients.
ImClone Systems and Bristol-Myers Squibb (BMS) have announced results from two randomized Phase III trials of Erbitux (cetuximab) in patients with metastatic colorectal cancer.
NovaDel Pharma announced that NitroMist (nitroglycerin lingual aerosol) has been approved by the FDA for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.
Tercica has reported that earlier this week its partner Ipsen submitted a new drug application (NDA) to the FDA for Somatuline Autogel (lanreotide acetate) injection, 60, 90 and 120 mg, to treat patients with acromegaly.